Trial · NCT01084551
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | International Restless Legs Syndrome Rating Scale (IRLS) Total Score | Baseline, the end of dose-titration/dose-maintenance period (week 13) | Full analysis set (FAS), last observation carried forward (LOCF) | Scores on a scale | MEAN |
| SECONDARY | Clinical Global Impression (CGI) Improvement | Baseline, the end of dose-titration/dose-maintenance period (week 13) | FAS, LOCF | Percentage of Participants | NUMBER |
| SECONDARY | Patient Global Impression (PGI) Improvement | Baseline, the end of dose-titration/dose-maintenance period (week 13) | FAS, LOCF | Percentage of Participants | NUMBER |
| SECONDARY | The Pittsburgh Sleep Quality Index (PSQI) | Baseline, the end of dose-titration/dose-maintenance period (week 13) | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | Each Item of IRLS (10 Items) | Baseline, the end of dose-titration/dose-maintenance period (week 13) | FAS, LOCF | percentage of participants | NUMBER |
| SECONDARY | Incidence of RLS Symptoms | Baseline, the end of dose-titration/dose-maintenance period (week 13) | FAS, LOCF | percentage of days with RLS symptom | MEAN |
| SECONDARY | Average Duration of RLS Symptoms | Baseline, the end of dose-titration/dose-maintenance period (weeks 13) | FAS, LOCF | Hours | MEAN |
| SECONDARY | Incidence of RLS Symptoms in the Evening and Night | Baseline, the end of dose-titration/dose-maintenance period (week 13) | FAS, LOCF | percentage of days/week with symptoms | MEAN |
| SECONDARY | Average Duration of RLS Symptoms in the Evening and Night in a Week | Baseline, the end of dose-titration/dose-maintenance period (weeks 13) | FAS, LOCF | Hours | MEAN |
| SECONDARY | Nocturnal Awakenings Due to RLS Symptoms in a Week | Baseline, the end of dose-titration/dose-maintenance period (week 13) | FAS, LOCF | percentage of days/week with awakening | MEAN |
| SECONDARY | Average Sleep Time in a Week | Baseline, the end of dose-titration/dose-maintenance period (weeks 13) | FAS, LOCF | Hours | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01084551/outcomes